natgillin/translations-raw huggingface dataset:
Adverse reactions attributed to mobilisation/apheresis System Organ Class (SOC) Very Common (≥10%)
Preglednica 1 Neželeni učinki, ki so pripisani mobilizaciji/aferezi Organski sistem
• excessive sweating
• težave z znojnicami
Headache
HIV.
Skin and subcutaneous tissue disorders
Bolezni kože in podkožja izpuščaj, hiperhidroza
Final results: Q4
Končni rezultati:
• fever
• hemeroidi
Nederland bluebird bio (Netherlands) B.V. Tel: +31 (0) 303 100 450
Tel.: +31 (0) 303 100 450
You should not be given Zynteglo if you are breast-feeding.
Če dojite, ne smete prejeti zdravila Zynteglo.
N=16, HGB-212), of whom 29 have a non-β0/β0 genotype (N=23, HGB-207; N=6, HGB-212) and 10 have a β0/β0 genotype in HGB-212.
N=14, HGB-207; N=1, HGB-212).
This is because Zynteglo is a gene therapy medicine.
zaradi zdravila Zynteglo.
• gallstones
• žolčni kamni
GENERAL CLASSIFICATION FOR SUPPLY
INFORMACIJE O DOBAVLJENIH SERIJAH
genotype, the MAH should submit interim and final data from patients with a severe non-β0/β0 genotype such as IVS-I-110 included in Study HGB-212.
Za potrditev učinkovitosti in varnosti zdravila Zynteglo pri bolnikih, starih 12 let in več, z β-talasemijo, odvisno od transfuzije (TDT), ki nimajo genotipa β0/β0, mora imetnik dovoljenja za promet predložiti vmesne in končne podatke za bolnike z resno, ki ni genotipa-β0/β0, kot je IVS-I-110, vključene v študijo HGB
Haematuria
Celice
HGB-204, HGB-205, HGB-207, LTF-303)
(N=10, HGB-204; N=4, HGB-205; N=15, HGB-207; N=3, HGB-212).
Alopecia, Pruritus, Skin hyperpigmentation
Bolezni kože in podkožja alopecija, pruritus,
Dizziness, Lethargy, Dysgeusia
generalizirani pruritus, purpura,
Splenomegaly, Leukocytosis
Bolezni krvi in limfatičnega sistema trombocitopenija splenomegalija, levkocitoza
Adverse reactions attributed to myeloablative conditioning
Preglednica 2 Neželeni učinki, ki so pripisani mieloablativnem postopku Organski sistem
Nervous system disorders
Žilne bolezni hipotenzija
It must also not be used in women who are breast-feeding.
Prav tako ga ne smejo uporabljati ženske, ki dojijo.
Treatment is continued for as long as the patient benefits from it.
Zdravljenje se nadaljuje tako dolgo, dokler je za bolnika koristno.
The European Commission granted a marketing authorisation valid throughout the European Union for Caprelsa on 17 February 2012.
Evropska komisija je dovoljenje za promet z zdravilom Caprelsa, veljavno po vsej Evropski uniji, izdala 17. februarja 2012.
The main measure of effectiveness was ‘overall response rate' (ORR) which considers several features of the disease.
Glavno merilo učinkovitosti je bil celotna stopnja odziva (ORR), ki upošteva številne značilnosti bolezni.
The study involved 331 patients and the main measure of effectiveness was progression-free survival (how long the patients lived without their disease getting worse).
V študijo je bilo vključenih 331 bolnikov, glavno merilo učinkovitosti pa je bil čas preživetja bolnikov brez napredovanja bolezni (kako dolgo so bolniki živeli, ne da bi se jim bolezen poslabšala).
The Committee noted the potential risk for QTc interval prolongation, and measures were introduced to minimise this risk.
Odbor je opozoril na možno tveganje podaljšanja intervala QTc in uvedel ukrepe za zmanjšanje tega tveganja.
What measures are being taken to ensure the safe and effective use of Caprelsa?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Caprelsa?
The full EPAR for Caprelsa can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Caprelsa je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This means that there is more evidence to come about the medicine, in particular on the size of the benefit in patients without the RET mutation.
To pomeni, da se pričakujejo dodatni dokazi o zdravilu, zlasti o obsegu koristi pri bolnikih brez mutacije RET.
This is a summary of the European public assessment report (EPAR) for Caprelsa.
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Caprelsa.
Of the 16 children treated with Caprelsa, 7 (44%) had partial response on the ORR scale, which was comparable to the response rate in adults.
Od 16 otrok, ki so bili zdravljeni z zdravilom Caprelsa, se jih je sedem (44 %) delno odzvalo na lestvici ORR, kar je primerljivo s stopnjo odziva pri odraslih.
By blocking the activity of EGF receptors, the cancer cells no longer receive the messages needed for growth and multiplication.
Z zaviranjem aktivnosti receptorjev EGF rakave celice več ne sprejemajo sporočil, potrebnih za rast in razmnoževanje.
On average, patients taking Caprelsa lived for 30.5 months without their disease getting worse, compared with 19.3 months for patients taking placebo.
Povprečno so bolniki, ki so jemali zdravilo Caprelsa , živeli 30,5 meseca brez poslabšanja bolezni, v primerjavi z 19,3 meseca pri bolnikih, ki so jemali placebo.
On average children taking Caprelsa lived for 46 months without their disease getting worse.
V povprečju so otroci, ki so jemali zdravilo Caprelsa, živeli 46 mesecev brez poslabšanja bolezni.
These enzymes are needed by certain receptors (such as VEGF, EGF and RET receptors) on the surface of cancer cells, where they activate several processes including cell division and the growth of new blood vessels.
Te encime potrebujejo nekateri receptorji (kot so receptorji VEGF, EGF in RET) na površini rakavih celic, kjer spodbujajo številne procese, vključno z delitvijo celic in rastjo novih žil.
The medicine is used when the disease is spreading quickly and causes symptoms, and when the cancer cannot be removed by surgery and has progressed or spread to other parts of the body.
Uporablja se, ko se bolezen hitro širi in povzroča simptome ter ko raka ni mogoče odstraniti operativno in je napredoval ali se je razširil na druge dele telesa.
The dose for children aged 5 years or older is calculated using the child's weight and height.
Odmerek za otroke, starejše od pet let, se izračuna na podlagi otrokove telesne mase in višine.
Patients who cannot swallow tablets can mix the tablet in plain (non-sparkling) water.
Bolniki, ki ne morejo pogoltniti tablet, lahko tableto razpustijo v navadni (negazirani) vodi.
By blocking the activity of VEGF receptors, the medicine reduces the blood supply to the cancer cells, slowing down the cancer's growth.
Z zaviranjem aktivnosti receptorjev VEGF zdravilo zmanjša oskrbo rakavih celic s krvjo in upočasni rast raka.
Caprelsa must not be used with other medicines that can prolong the QTc interval.
Zdravilo Caprelsa se ne sme uporabljati skupaj z drugimi zdravili, ki lahko podaljšajo interval QTc.
This means that it blocks the activity of enzymes known as tyrosine kinases.
To pomeni, da zavira delovanje encimov, imenovanih tirozin-kinaze.
It must not be used in people with a problem called ‘congenital long QTc syndrome' or who have a QTc interval longer than 480 milliseconds.
Ne sme se uporabljati pri osebah z motnjo, imenovano prirojeni sindrom podaljšanega intervala QTc, ali tistih, pri katerih je interval QTc daljši od 480 milisekund.
What benefits of Caprelsa have been shown in the studies?
Kakšne koristi je zdravilo Caprelsa izkazalo v študijah?
However, it was uncertain how well it works in patients without a mutation (change) in a gene called the ‘rearranged during transfection' (RET) gene or in patients whose RET mutation status is not known.
Vendar ni bil prepričan, kako dobro deluje pri bolnikih brez mutacije (spremembe) v genu, imenovanem „med transfekcijo prerazporejeni gen“ (gen RET), ali pri bolnikih, pri katerih stanje mutacije RET ni znano.
Patients must be given a patient alert card containing important safety information and they must be informed by their doctor about the risks of Caprelsa.
Bolniki morajo prejeti opozorilno kartico, ki vsebuje pomembne informacije o varnosti, zdravnik pa jim mora pojasniti tveganja, povezana z zdravilom Caprelsa.
What is Caprelsa and what is it used for?
Kaj je zdravilo Caprelsa in za kaj se uporablja?
The most commonly reported side effects with Caprelsa are diarrhoea, rash, nausea (feeling sick), high blood pressure and headache.
Najpogostejši neželeni učinki, o katerih so poročali pri uporabi zdravila Caprelsa, so driska, izpuščaj, navzeja (slabost), visok krvni tlak in glavobol.
Other information about Caprelsa
Druge informacije o zdravilu Caprelsa
It is not intended to provide practical advice on how to use Caprelsa.
Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
What are the risks associated with Caprelsa?
Kakšna tveganja so povezana z zdravilom Caprelsa?
In a main study, Caprelsa was more effective than placebo (a dummy treatment) in adults with medullary thyroid cancer that could not be removed by surgery or had spread to other parts of the body.
V glavni študiji je bilo zdravilo Caprelsa učinkovitejše od placeba (zdravila brez zdravilne učinkovine) pri odraslih z medularnim rakom ščitnice, ki ga ni bilo mogoče kirurško odstraniti ali se je razširil na druge dele telesa.
The active substance in Caprelsa, vandetanib, is a ‘protein tyrosine kinase inhibitor'.
Zdravilna učinkovina v zdravilu Caprelsa, vandetanib, je „zaviralec protein-tirozin-kinaze“.
The CHMP concluded that the benefits of Caprelsa outweigh its risks in patients whose disease is spreading quickly and is causing symptoms, since they are in urgent need of treatment.
Sklenil je, da so koristi zdravila Caprelsa večje od z njim povezanih tveganj pri tistih bolnikih, pri katerih se bolezen širi hitreje in povzroča simptome, saj zdravljenje nujno potrebujejo.
The doctor may temporarily stop Caprelsa treatment and reduce the dose if the patient has abnormal ECG or severe side effects.
Zdravnik lahko zdravljenje z zdravilom Caprelsa začasno prekine in zmanjša odmerek, če ima bolnik nenormalen EKG ali se pri njem pojavijo hudi neželeni učinki.
Why is Caprelsa approved?
Zakaj je bilo zdravilo Caprelsa odobreno?
Caprelsa can affect the electrical activity of the heart including a measurement called QTc interval.
Zdravilo Caprelsa lahko vpliva na električno dejavnost srca, vključno na merjenje tako imenovanega intervala QTc.
Vandetanib also blocks the activity of RET receptors, which play a role in the growth of medullary thyroid cancer cells.
Vandetanib zavira tudi aktivnost receptorjev RET, ki sodelujejo pri rasti celic medularnega raka ščitnice.
The medicine can only be obtained with a prescription and treatment with Caprelsa should be started and supervised by a doctor who has experience of treating medullary thyroid cancer, of using cancer medicines and of assessing electrocardiograms (ECG, a test that measures the electrical activity of the heart).
Predpisovanje in izdaja zdravila je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik, ki ima izkušnje z zdravljenjem medularnega raka ščitnice, z uporabo zdravil proti raku in ocenjevanjem s pomočjo elektrokardiograma (EKG, tj. testa, ki meri električno aktivnost srca).
The company that markets Caprelsa will ensure that doctors who are expected to prescribe Caprelsa receive educational material containing important safety information about Caprelsa, including measures to manage the risk of QTc prolongation and other potential side effects, and a patient alert card and guidance for children or their carers.
Družba, ki trži zdravilo Caprelsa, bo zdravnikom, za katere se pričakuje, da bodo zdravilo Caprelsa predpisovali, priskrbela izobraževalno gradivo, ki bo vsebovalo pomembne informacije o varnosti zdravila Caprelsa, vključno z ukrepi za obvladovanje tveganja podaljšanja intervala QTc in drugih možnih neželenih učinkov, ter opozorilno kartico za bolnike in navodila za otroke oziroma njihove skrbnike.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Caprelsa have also been included in the summary of product characteristics and the package leaflet.
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Caprelsa upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.
What information is still awaited for Caprelsa?
Katere informacije o zdravilu Caprelsa še pričakujemo?
Caprelsa is available as tablets (100 mg and 300 mg) and the recommended dose for adults is 300 mg once a day, taken at around the same time each day.
Priporočeni odmerek za odrasle je 300 mg enkrat na dan, ki ga je treba vzeti vsak dan ob približno istem času.
Caprelsa is a cancer medicine that is used in adults and children above 5 years of age to treat medullary thyroid cancer, a cancer that starts off in the cells in the thyroid gland that produce the hormone calcitonin.
Caprelsa je zdravilo proti raku, ki se uporablja pri odraslih in otrocih, starejših od pet let, za zdravljenje medularnega raka ščitnice, tj. raka, ki se začne v celicah v ščitnici, ki proizvajajo hormon kalcitonin.
For more information about treatment with Caprelsa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Za več informacij o zdravljenju z zdravilom Caprelsa preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
In a second main study, Caprelsa was given to children aged between 9 and 17 years with hereditary medullary thyroid cancer.
V drugi glavni študiji so zdravilo Caprelsa dali otrokom, starim med devet in 17 let, z dednim medularnim rakom ščitnice.
It is recommended that the doctor checks for RET mutation at the start of Caprelsa treatment.
Priporoča se, da zdravnik na začetku zdravljenja z zdravilom Caprelsa preveri mutacijo RET.
Caprelsa has been given ‘conditional approval'.
Zdravilo Caprelsa je pridobilo „pogojno dovoljenje za promet“.
The CHMP concluded that Caprelsa was shown to be effective in the treatment of medullary thyroid cancer in patients aged 5 years and older.
CHMP je zaključil, da je zdravilo Caprelsa učinkovito pri zdravljenju medularnega raka ščitnice pri bolnikih, starejših od pet let.
The company that markets Caprelsa will carry out a study in patients with medullary thyroid cancer to compare the effects of Caprelsa in patients with and without the RET mutation.
Družba, ki trži zdravilo Caprelsa, bo opravila študijo pri bolnikih z medularnim rakom ščitnice, da bo primerjala učinke zdravila Caprelsa pri bolnikih z mutacijo RET in brez nje.
For the full list of all side effects reported with Caprelsa, see the package leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Caprelsa, glejte navodilo za uporabo.
For practical information about using Caprelsa, patients should read the package leaflet or contact their doctor or pharmacist.
Za praktične informacije o uporabi zdravila Caprelsa naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
Therefore, the Committee recommended that Caprelsa be granted marketing authorisation.
Zato je priporočil, da se za zdravilo Caprelsa izda dovoljenje za promet.
Caprelsa may work less well in patients without a mutation (change) in a gene called the ‘rearranged during transfection' (RET) gene.
Zdravilo Caprelsa bo morda manj učinkovito pri bolnikih, ki nimajo mutacije (spremembe) gena, imenovanega gen RET ali „med transfekcijo prerazporejeni gen“.
How does Caprelsa work?
Kako zdravilo Caprelsa deluje?
Caprelsa contains the active substance vandetanib.
Zdravilo Caprelsa vsebuje zdravilno učinkovino vandetanib.
How is Caprelsa used?
Kako se zdravilo Caprelsa uporablja?
Therefore they should be used with caution.
Zato jih je treba uporabljati previdno.
MARKETING AUTHORISATION NUMBER(S) EU/2/02/035/007
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/02/035/007
• Avoid contact by mouth.
• Izogibajte se stiku preko ust.
Elimination from blood is largely complete within 24 hours.
Odstranjevanje iz krvi je v glavnem končano v 24 urah.
This is an idiosyncratic response very occasionally seen after repeated exposure.
To je idiosinkratičen odziv, ki ga po ponovnem izpostavljanju vidimo precej redko.
The half-life for the slow elimination phase is approximately 50 minutes.
Razpolovni čas za počasno fazo odstranjevanja iz telesa je približno 50 minut.
• Do not inhale the vapour directly.
• Ne vdihavajte hlapov neposredno.
The elimination of sevoflurane is biphasic in nature, with an initial rapid phase and a second, slower phase.
Odstranjevanje sevoflurana iz telesa je po naravi bifazično, z začetno hitro fazo in drugo, počasnejšo fazo.
If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.
Če opazite kakršne koli stranske tudi tiste, ki niso navedeni v tem navodilu za uporabo ali mislite da zdravilo ni delovalo, obvestite svojega veterinarja.
Interaction with other veterinary medicinal products and other forms of interaction
Medsebojno delovanje z drugimi veterinarskimi zdravili in druge oblike interakcij
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 11 December 2002
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum pridobitve dovoljenja za promet: 11. december 2002
Advice to doctors: Maintain a patent airway and give symptomatic and supportive treatment.
Nasvet za zdravnike: Vzdržujte odprto zračno pot in nudite simptomatsko in podporno zdravljenje.
Appropriate treatment should readily be instituted.
Takoj je treba začeti z ustreznim zdravljenjem.
Shelf-life of the veterinary medicinal product as packaged for sale: 3 years 6.4 Special precautions for storage
Rok uporabnosti zdravila v pakiranju za produjo: 3 leti 6.4 Posebna navodila za shranjevanje
Active substance: Each bottle contains 250 ml sevoflurane (100%).
Učinkovina: Vsaka steklenica vsebuje 250 ml sevoflurana (100 %).
Adjustment is, therefore, left to the discretion of the veterinarian.
Prilagoditev je zato prepuščena presoji veterinarja.
• From an environmental point of view, it is considered good practice to use charcoal filters with scavenging equipment.
• S stališča varstva okolja velja za dobro prakso, da pri opremi za čiščenje zraka uporabljamo filtre iz oglja.
The Minimum Alveolar Concentration (MAC) of sevoflurane in dogs is 2.36% and the MAC in cats 3.1%.
Minimalna alveolarna koncentracija (MAC) sevoflurana pri psih je 2,36 % in MAC pri mačkah je 3.1%.
Therefore, the lack of significant colour change should not be taken as an assurance of adequate hydration.
Zato odsotnosti pomembne spremembe barve ne smete razumeti, kot da to zagotavlja zadostno hidracijo.
If these symptoms occur, the individual should be removed from the source of exposure and medical attention sought.
Če se pojavijo ti simptomi, je treba osebo odstraniti od vira izpostavljenosti in poiskati zdravniško pomoč.
Therefore, respiration must be monitored closely and supported when necessary with supplementary oxygen and/or assisted ventilation.
Zato je treba dihanje skrbno spremljati in ga podpirati, če je potrebno, z dodatnim kisikom in/ali asistirano ventilacijo.
• Pregnant and breast-feeding women should not have any contact with the product and should avoid operating rooms and animal recovery areas.
• Nosečnice in doječe matere ne smejo priti v stik z zdravilom in se morajo izogibati operacijskim sobam in prostorom za prebujanje živali.
Use only according to the risk/benefit assessment of the responsible veterinarian.
Uporabite le v skladu z oceno razmerja korist/tveganje odgovornega veterinarja.
Multiples of MAC are used as a guide for surgical levels of anaesthesia, which are typically 1.3 to 1.5 times the MAC value.
Mnogokratniki MAC se uporabljajo kot smernica za kirurške ravni anestezije, ki so tipično 1,3 do 1,5-kratnik vrednosti MAC.
Sevoflurane is metabolised to a limited extent in the dog (1 to 5%).
Sevofluran se pri psu presnavlja v omejenem obsegu (1 do 5 %).
There are limited data to support the safety of sevoflurane in animals less than 12 weeks of age.
Podatki o varnosti sevoflurana pri živalih, mlajših od 12 tednov, so omejeni.
Excipient(s) For the full list of excipients, see section 6.1.
Pomožna(pomožne) snov(i): Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
Sevoflurane concentration for induction may be set initially, or may be achieved gradually over the course of 1 to 2 minutes.
Koncentracije sevoflurana lahko nastavimo že v začetku ali jih dosežemo postopoma v 1 do 2 minutah.
• All scavenging/extraction systems must be adequately maintained.
• Vse sisteme za prečiščevanje zraka je treba ustrezno vzdrževati.
However, it is recommended that such animals be monitored carefully during sevoflurane anaesthesia.
Vendar priporočajo, da takšne živali med sevofluransko anestezijo skrbno spremljamo.
SevoFlo contains no stabiliser and does not affect the calibration or operation of these vaporisers in any way.
SevoFlo ne vsebuje nobenega stabilizatorja in nikakor ne vpliva na kalibracijo ali delovanje teh hlapilnikov.
Therefore, it should only be used in these animals according to a benefit-risk assessment by the responsible veterinary surgeon.
Zato ga je treba pri teh živalih uporabljati le v skladu z oceno tveganja in koristi, ki jo opravi odgovorni veterinar.
CO2 absorbents should be replaced routinely regardless of the state of the colour indicator.
Absorberje za CO2 morate redno menjavati ne glede na stanje barvnega indikatorja.
• Ensure that operating rooms and animal recovery areas are provided with adequate ventilation or scavenging systems to prevent the accumulation of anaesthetic vapour.
• Poskrbite, da bodo operacijske sobe in prostori za prebujanje živali opremljene z ustreznimi prezračevalnimi ali čistilnimi sistemi, ki bodo preprečevali kopičenje hlapov anestetika.
Phenothiazines and alpha-2-agonists:
Fenotiazini in alfa-2-agonisti:
MANUFACTURER'S BATCH NUMBER Lot {number}
PROIZVAJALČEVA ŠTEVILKA SERIJE Serija {številka}
In dogs with head injuries or other conditions placing them at risk from increased ICP, it is recommended that hypocapnia be induced by means of controlled hyperventilation as a means of preventing changes in ICP.
Pri psih s poškodbami glave ali drugimi boleznimi, zaradi katerih jih ogroža zvišani ICP, priporočajo kot sredstvo za preprečevanje sprememb ICP indukcijo hipokapnije s pomočjo kontrolirane hiperventilacije.
If it is suspected that the CO2 absorbent may be desiccated, it must be replaced.
Če posumite, da bi utegnil biti absorber za CO2 posušen, ga morate zamenjati.
Sevoflurane produces unconsciousness by its action on the central nervous system.
Sevofluran povzroča nezavest z delovanjem na centralno živčevje.
The presence of surgical stimulation may require an increase in the concentration of sevoflurane.
Prisotnost kirurške stimulacije utegne zahtevati zvišanje koncentracije sevoflurana.
Neuromuscular blocking agents have been used in cats anaesthetised with sevoflurane without any unexpected effects.
Neuromuskularni blokatorji so bili uporabljeni pri mačkah, anesteziranih s sevofluranom, brez nepričakovanih učinkov.
1,1,3,3,3-pentafluoro-2-(fluoromethoxy)propene (C4H2F6O), also known as Compound A, is produced when sevoflurane interacts with soda lime or barium hydroxide.
1,1,3,3,3-pentafluoro-2-(fluorometoksi)propen (C4H2F6O), znan tudi kot spojina A, nastaja, kadar sevofluran reagira z zmesjo kalcijevega hidroksida z natrijevim ali kalijevim hidroksidom ali barijevim hidroksidom.
For inhalation use only, using a suitable carrier gas.
Samo za uporabo z inhaliranjem ob uporabi primernega nosilnega plina.
If eye exposure occurs, the eye should be flushed with plenty of water for 15 minutes.
Če pride do izpostavljenosti očesa, je treba oko 15 minut spirati z veliko vode.
Preanaesthetic doses for premedicants may be lower than the label directions for their use as a single medication.
Preanestetični odmerki zdravil za premedikacijo utegnejo biti manjši od tistih, ki so navedeni v navodilih za njihovo uporabo kot edinega zdravila.
• Avoid using masking procedures for prolonged induction and maintenance of general anaesthesia.
• Ne uporabljajte postopkov z masko za dolgotrajno uvajanje in vzdrževanje splošne anestezije.